# Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children

> **NCT07022834** · PHASE2 · RECRUITING · sponsor: **West China Second University Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Langerhans Cell Histiocytosis (LCH)

## Interventions

- **DRUG:** Dabrafenib or Trametinib and Clofarabine

## Key facts

- **NCT ID:** NCT07022834
- **Lead sponsor:** West China Second University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2028-06-01
- **Final completion:** 2030-06-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07022834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07022834, "Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07022834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*